IBD-PODCAST GERMANYProportion of Inadequate Disease Control And Strategy of Treatment in IBD

• Conditions: K51; K50; Ulcerative colitis; Crohn disease [regional enteritis]

• Registration Number: DRKS00027278
• Lead Sponsor: AbbVie Deutschland GmbH & Co. KG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-10
• Study Completion: 2022-12-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 499

Inclusion Criteria

Patients are eligible to participate in this observational study if they meet the following requirements:
- = 19 years at the time of study entry
- Confirmed diagnosis of UC or CD = 1 year prior to study entry, including site documentation
- Ready and able to provide informed consent
- Ready and able to read, understand and answer patient study materials

Exclusion Criteria

Patients are not eligible to participate in this observational study if:
- documentation in the medical file < 12 months
- current study drug/non-approved device/intervention treatment
- diagnosis of IBDU (non-classified IBD)
- history of proctocolectomy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- Insufficient disease control (yes/no) of Crohn's disease (CD) at index date, defined as patients with one or more red flags indicating insufficient disease control <br> - Insufficient disease control (yes/no) of ulcerative colitis (UC) at index date, defined as patients with one or more red flags indicating insufficient disease control<br>- short inflammatory bowel disease questionnaire (SIBDQ) scores in CD patients inadequately or adequately controlled at index date<br> - SIBDQ scores in UC patients inadequately or adequately controlled at index date